GSTM1 and cardiovascular disorder: Several large-scale randomized controlled trials, which compared the benefit of target Hb level as normal (>13 g/dL) versus lower (10–11 g/dL) on mortality and cardiovascular disease (CVD) events, have consistently shown increased risk and no incremental improvement in the quality of life of normalizing Hb levels [14–16].